Advertisement

Topics

Aeglea Biotherapeutics, Inc. Company Profile

19:24 EST 13th December 2018 | BioPortfolio

Aeglea was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.


News Articles [232 Associated News Articles listed on BioPortfolio]

Aeglea BioTherapeutics Announces Positive Clinical Update

Aeglea BioTherapeutic issued an update on Tuesday for its ongoing Phase 1/2 trial of pegzilarginase in patients with a rare genetic disease, Arginase 1 Deficiency (ARG1-D). The post Aeglea BioTherapeu...

Aeglea BioTherapeutics Announces Positive Clinical Updates

While some companies wait until clinical trials are finished with dosing and collecting data to begin releasing information, those that release interim data can give investors a better handle on how t...

Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase

Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today a...

Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow

$AGLE announces New Positive Interim Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency https://finance.yahoo.com/news/aeglea-biotherapeutics-announces-positive-interim-110

$AGLE announces New Positive Interim Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency https://finance.yahoo.com/n...

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

AUSTIN, Texas, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for p...

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency

Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1 2021 Company to Host Conference Call Today ...

Aeglea BioTherapeutics Inc AGLE Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 07092018] Prices from USD $250

SummaryAeglea BioTherapeutics Inc Aeglea BioTherapeutics, formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the tre...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [24 Associated PubMed Articles listed on BioPortfolio]

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In ...

Cell Penetration Profiling Using the Chloroalkane Penetration Assay.

Biotherapeutics are a promising class of molecules in drug discovery, but they are often limited to extracellular targets due to their poor cell penetration. High-throughput cell penetration assays ar...

Live bacterial biotherapeutics in the clinic.

Data-independent oxonium ion profiling of multi-glycosylated biotherapeutics.

The characterization of glycosylation is required for many protein therapeutics. The emergence of antibody and antibody-like molecules with multiple glycan attachment sites has rendered glycan analysi...

Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.

The extensive analytical characterization of protein biotherapeutics, especially of biosimilars, is a critical part of the product development and registration. High-resolution mass spectrometry becam...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [106 Associated Companies listed on BioPortfolio]

Aeglea Biotherapeutics, Inc.

Aeglea was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

More Information about "Aeglea Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Aeglea Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Aeglea Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Aeglea Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aeglea Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Aeglea Biotherapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record